Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticarcillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | RECQL | P46063 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 1/20 | 0.59 |
| ▸ | RARG | P13631 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticarcillin SCHEMBL10738085 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL5047437 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738099 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL34025 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL193733 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL28757995 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL9929365 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935398 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4228859 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL27742456 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | PTGS1 668/4885SMN1; SMN2 2277/4885KDM4E 2934/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | PTGS1 1076/4885SMN1; SMN2 759/4885KDM4E 1674/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | PTGS1 908/4885SMN1; SMN2 4229/4885KDM4E 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.